ArticleAsia-Pacific journal of clinical oncology2026
Does Limited-Margin Radiotherapy Change the Recurrence Pattern and Survival of Patients With IDH-Wild-Type Glioblastoma? Analysis and Validation of a Different Approach.
Article in Asia-Pacific journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Does Limited-Margin Radiotherapy Change the Recurrence Pattern and Survival of Patients With IDH-Wild-Type Glioblastoma? Analysis and Validation of a Different Approach.Asia-Pacific journal of clinical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe aimed to analyze our radiotherapy protocol by evaluating its effect on recurrence patterns and survival outcomes.
methodsWe assessed 69 patients diagnosed with IDH-wild-type glioblastoma who underwent chemoradiotherapy at our institution from January 2014 to January 2021. A high-risk clinical target volume (CTV
resultsWith a median follow-up of 21 months, 88.4% of patients experienced recurrence. The overall survival rates at 1, 2, and 5 years were 84.1%, 51.5%, and 17%, respectively. The progression-free survival rates at the same intervals were 44.9%, 21.5%, and 9.5%, respectively. Recurrence patterns were central in 63.9%, in-field in 18%, marginal in 4.9%, and distant in 13.1%.
conclusionThe recurrence pattern remained unchanged with our protocol. With longer survival times, distant recurrence rates increase, yet central and in-field recurrences remain dominant. Despite the decrease in the volume that received the 60 Gy dose, marginal recurrences remained at a notably low level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.